LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Stock List・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Closed

SectorHealthcare

16.62 -0.12

Buy Sell

Overview

Share price change

24h

Current

Min

16.59

Max

16.71

Key metrics
By Trading Economics
Income	117B 106B
Sales	100B 1.2T
P/E Sector Avg	71.13 51.415
EPS	0.21
Dividend yield	4.04
Profit margin	8.697
Employees	47,455
EBITDA	140B 456B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+26.2% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	4.04% 2.34%

Market Stats
By TradingEconomics
Market Cap	-3.6B 52B
Previous open	16.74
Previous close	16.62

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 15.16 Support & Resistance

Takeda Pharmaceutical Co Ltd ADR Chart

Past performance is not a reliable indicator of future results.

Related News

13 May 2026, 08:59 UTC

Earnings

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29 Jan 2026, 07:11 UTC

Earnings

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 Dec 2025, 03:32 UTC

Major Market Movers

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 Oct 2025, 09:39 UTC

Earnings

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 Oct 2025, 07:32 UTC

Earnings

Takeda Posts Quarterly Net Loss, Cuts Guidance

13 May 2026, 06:57 UTC

Earnings

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13 May 2026, 06:54 UTC

Earnings

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13 May 2026, 06:44 UTC

Earnings

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13 May 2026, 06:38 UTC

Earnings

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13 May 2026, 06:31 UTC

Earnings

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13 May 2026, 06:31 UTC

Earnings

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 May 2026, 06:31 UTC

Earnings

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 May 2026, 06:31 UTC

Earnings

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13 May 2026, 06:31 UTC

Earnings

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 May 2026, 06:31 UTC

Earnings

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29 Jan 2026, 06:53 UTC

Earnings

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 Jan 2026, 06:36 UTC

Earnings

Takeda Raises FY Revenue, Net-Profit Views

29 Jan 2026, 06:34 UTC

Earnings

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 Jan 2026, 06:33 UTC

Earnings

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 Jan 2026, 06:32 UTC

Earnings

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 Jan 2026, 06:30 UTC

Earnings

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 Jan 2026, 06:30 UTC

Earnings

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 Jan 2026, 06:30 UTC

Earnings

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 Jan 2026, 06:30 UTC

Earnings

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 Jan 2026, 06:30 UTC

Earnings

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 Jan 2026, 06:30 UTC

Earnings

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 Oct 2025, 07:10 UTC

Earnings

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 Oct 2025, 06:50 UTC

Earnings

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 Oct 2025, 06:49 UTC

Earnings

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 Oct 2025, 06:48 UTC

Earnings

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Peer Comparison

Price change

Takeda Pharmaceutical Co Ltd ADR Forecast

Price Target

By TipRanks

26.2% upside

12 Months Forecast

Average 21 USD 26.2%

High 21 USD

Low 21 USD

Based on 1 Wall Street analysts offering 12 month price targets forTakeda Pharmaceutical Co Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Takeda Pharmaceutical Co Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 15.16Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.